Loading...

Virios Therapeutics, Inc.

VIRINASDAQ
Healthcare
Biotechnology
$0.15
$0.02(12.40%)

Virios Therapeutics, Inc. (VIRI) Stock Overview

Explore Virios Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.4/100

Key Financials

Market Cap206.5K
P/E Ratio-0.00
EPS (TTM)$-5.75
ROE-14.13%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$3.22

VIRI Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Virios Therapeutics, Inc. (VIRI) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $3.22.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 206.5K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for VIRIStats details for VIRI are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations

Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0

Price Targets

Low$0.00
Average$0.00
High$0.00

Company Profile

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

CEO

Mr. Gregory Duncan

Employees

4

Headquarters

44 Milton Avenue, Alpharetta, GA

Founded

2020

Frequently Asked Questions

;